Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Patient Assistance Program
Don’t let the high cost of targeted radioligand therapy disrupt your PSMA-positive metastatic castration-resistant prostate cancer treatment. We help eligible patients access Pluvicto through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is FDA-approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in adults previously treated with androgen receptor pathway inhibitor and taxane-based chemotherapy. PSMA-targeted radioligand therapy given as IV infusions in certified centers.
- Without assistance, Pluvicto costs approximately $42,000+ per dose, with a course of up to 6 doses.
- Through AffordMyPrescriptions, qualifying patients can access Pluvicto assistance for a flat $69.95 per month.
- Pluvicto requires PSMA-PET imaging confirmation and is administered in certified nuclear medicine centers every 6 weeks for up to 6 doses. Other advanced prostate cancer options include AR pathway inhibitors (Xtandi, Nubeqa, Erleada, Zytiga), taxane chemotherapy, Xofigo, and PARP inhibitors for select mutations. Support: ZERO Prostate Cancer, Prostate Cancer Foundation.
What is Pluvicto Prescription Assistance Program?
The Pluvicto Patient Assistance Program helps eligible patients access this PSMA-targeted radioligand therapy at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Pluvicto PAP enrollment for a flat $69.95 per month — so you never face a gap in your prostate cancer therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Pluvicto enrollment — so you never face a gap in treatment.
Pharmacy Price Comparison
- Without assistance, Pluvicto costs tens of thousands per dose. A Patient Assistance Program can offset costs if you qualify:
| SETTING | PRICE PER DOSE | YOU SAVE W/ US |
|---|---|---|
| Certified treatment center | ~$42,500/dose | Save substantially |
| Hospital outpatient | ~$45,000/dose | Save substantially |
| Academic cancer center | ~$43,000/dose | Save substantially |
| Full course (up to 6 doses) | ~$255,000 total | Save substantially |
| Plus PSMA-PET imaging | ~$3,000+ | Coordinated |
*Retail prices are estimates based on public data and vary by treatment center. Pluvicto is administered as a series of infusions in certified centers. AffordMyPrescriptions Advocacy Service works with the manufacturer’s assistance program to secure your Pluvicto — independent of per-dose retail pricing.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Pluvicto Prescription Program?
The Pluvicto Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Pluvicto is a specialized radioligand therapy administered in certified nuclear medicine or oncology centers. It requires PSMA-PET imaging confirmation. Coordination with the treatment center is essential.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Pluvicto assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your treatment center and the assistance program.
Receive Medication
Once approved, your Pluvicto is coordinated through the assistance program at a certified center while we manage the paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Discount cards do not apply to radioligand therapies given in treatment centers. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better solution for Pluvicto:
Limitations of Coupons
Discount cards do not apply to radioligand therapies given in treatment centers
Copay accumulators may prevent savings from counting toward your deductible
Prices vary by center and are not negotiable at the pharmacy counter
Still tens of thousands of dollars per dose without assistance
Cannot be used with certain government insurance in the usual copay-card way
Advantages of PAP Through Us
Fixed $69.95/month advocacy — never changes regardless of per-dose price
- No expiration — continuous support across your full treatment course
Treatment coordinated directly through the assistance program
We manage all paperwork, documentation, and renewals
Medicare beneficiaries assisted where programs allow
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Pluvicto assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Pluvicto Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Pluvicto:
Pluvicto is a PSMA-targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with androgen receptor pathway inhibition and taxane-based chemotherapy. A precision nuclear medicine treatment.
How It Works:
Prostate-specific membrane antigen (PSMA) is highly expressed on the surface of most prostate cancer cells, making it an ideal target for precision therapy. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand — a targeting molecule that binds PSMA linked to the radioactive isotope lutetium-177. After IV infusion, Pluvicto circulates and binds to PSMA-expressing prostate cancer cells throughout the body. The bound lutetium-177 emits beta radiation that damages the DNA of the targeted cells and nearby tumor cells, causing cell death while limiting exposure to surrounding healthy tissue. Because it targets PSMA specifically, Pluvicto delivers radiation directly to metastatic deposits. Eligibility requires a PSMA-PET scan (such as with a PSMA-targeted imaging agent) confirming PSMA-positive disease before treatment.
Form and Use:
Pluvicto IV infusion, given once every 6 weeks for up to 6 doses, in a certified nuclear medicine or oncology treatment center. Requires PSMA-PET imaging to confirm PSMA-positive disease. Radiation safety precautions apply for a short period after each dose. Blood counts, kidney function, and other labs monitored.
Generic Availability:
No generic Pluvicto — it is a specialized radioligand therapy. Related PSMA-targeted imaging agents (Locametz/gallium-68 gozetotide, Pylarify/piflufolastat F-18) are used to identify eligible patients. Other advanced prostate cancer therapies: androgen receptor pathway inhibitors (Xtandi/enzalutamide, Erleada/apalutamide, Nubeqa/darolutamide, Zytiga/abiraterone), taxane chemotherapy (docetaxel, cabazitaxel), radium-223 (Xofigo — for bone metastases), PARP inhibitors (Lynparza, Rubraca) for certain mutations. Prostate cancer support: ZERO Prostate Cancer, Prostate Cancer Foundation, Us TOO.
Warnings:
Radiation exposure risks (follow radiation safety precautions to protect household and caregivers), myelosuppression (low blood counts — anemia, thrombocytopenia, leukopenia; monitor blood counts), renal toxicity (stay hydrated; kidney function monitored), dry mouth (radiation to salivary glands), nausea and fatigue, embryo-fetal/genotoxicity considerations (may impair fertility). Common: fatigue, dry mouth, nausea, decreased appetite, low blood counts. Administered only in certified centers with nuclear medicine expertise.
FAQ (Frequently Asked Questions)
How much does Pluvicto cost without insurance?
Approximately $42,000–$45,000 per dose, with a full course of up to 6 doses reaching around $255,000, plus PSMA-PET imaging costs. It is among the most expensive prostate cancer therapies.
Do I need a special scan before Pluvicto?
Yes. Pluvicto is only for PSMA-positive disease, confirmed by a PSMA-PET scan using a PSMA-targeted imaging agent (such as Locametz or Pylarify). This ensures your cancer expresses the PSMA target that Pluvicto binds.
How is Pluvicto given?
As an IV infusion in a certified nuclear medicine or oncology center, once every 6 weeks for up to 6 doses. Because it is radioactive, short-term radiation safety precautions protect your household and caregivers after each dose.
What are Pluvicto's main side effects?
Fatigue, dry mouth, nausea, decreased appetite, and low blood counts (anemia, low platelets, low white cells). Kidney function and blood counts are monitored, and staying hydrated helps protect the kidneys.
When is Pluvicto used in prostate cancer treatment?
After PSMA-positive mCRPC has progressed on an androgen receptor pathway inhibitor (such as Xtandi or Zytiga) and taxane-based chemotherapy. It offers a targeted option when other standard treatments have been used.
Take Control of Your Medication Costs
Targeted radioligand therapy has transformed advanced prostate cancer care. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.